COMBINED THERAPY, INCLUDING VEMURAFENIB AND INTERFERON, FOR USE IN TREATMENT OF CANCER

摘要

1. A pharmaceutical product containing (A) a first component that contains, as an active agent, {3- [5- (4-chloro-phenyl) -1H-pyrrolo [2,3-b] pyridin-3-carbonyl-2, 4-difluoro-phenyl] -amide} propan-1-sulfonic acid or a pharmaceutically acceptable salt thereof; and (B) a second component that contains interferon as an active agent; as a combined preparation for the simultaneous or sequential use in the treatment of a proliferative disease, in particular cancer, more specifically colorectal cancer, melanoma and thyroid cancer with b-Raf with a mutation V600.2. The pharmaceutical product of claim 1 for the simultaneous or sequential use in the treatment of a proliferative disease, in particular cancer, more specifically colorectal cancer, melanoma and thyroid cancer, with the presence of b-Raf with a mutation V600E. The pharmaceutical product according to claim 1 for simultaneous or sequential use in the treatment of melanoma containing b-Raf with a mutation V600E. The pharmaceutical product according to claim 1, wherein {3- [5- (4-chloro-phenyl) -1H-pyrrolo [2,3-b] pyridin-3-carbonyl-2,4-difluoro-phenyl] amide} propan-1-sulfonic acid or a pharmaceutically acceptable salt thereof is administered in an amount of from about 200 mg / day to about 3000 mg / day. The pharmaceutical product according to claim 1, wherein the {3- [5- (4-chloro-phenyl) -1H-pyrrolo [2,3-b] pyridin-3-carbonyl-2,4-difluoro-phenyl] amide propane -1-sulfonic acid or a pharmaceutically acceptable salt thereof is administered in an amount of from about 1700 mg / day to about 2100 mg / day. The pharmaceutical product according to claim 1, wherein said interferon is peginterferon alfa-2a. The pharmaceutical product according to claim 6, in which